This article is freely available to all

Prim Care Companion CNS Disord 2022;24(3):21cr03098

To cite: Locke D, Diaz A. Young-onset dementia with Lewy bodies with Capgras syndrome. Prim Care Companion CNS Disord. 2022;24(3):21cr03098.
To share: https://doi.org/10.4088/PCC.21cr03098

© Copyright 2022 Physicians Postgraduate Press, Inc.

aPennsylvania State University College of Medicine, Hershey, Pennsylvania
bDepartment of Psychiatry and Behavioral Health, Pennsylvania State University College of Medicine, Hershey, Pennsylvania
*Corresponding author: Ailyn Diaz, MD, Department of Psychiatry and Behavioral Health, 500 University Dr, Hershey, PA 17033 ([email protected]).

 

 

Dementia with Lewy bodies (DLB) is a commonly underdiagnosed neurodegenerative disease with a known association with delusional misidentification syndromes, such as Capgras syndrome (CS), that is associated in studies1–4 with a concurrence rate between 8% and 40% in clinical cases. It is important to note that DLB rarely occurs as young-onset dementia before the age of 65 years, accounting for 4% of all patient cases.5,6 The neuropsychiatric symptoms of DLB are characterized by fluctuations in mental status, visual hallucinations, rapid eye movement sleep behavior disorder, autonomic dysfunction, and parkinsonian motor symptoms.1,7 One small study3 indicated that 81% of CS patients concurrently had a neurodegenerative disease, most frequently DLB. CS is understood to stem from disconnections in the pathway between the facial processing center in the temporal lobe and the personal/emotional stimulus centers in the limbic system8 as well as an inability to reject delusional beliefs.9 Current treatment for CS is based around the treatment of the underlying disorder.10 Some evidence suggests that patients with CS due to DLB may benefit from cholinesterase inhibitors and antipsychotics.11

Case Report

Mr A is a 53-year-old Hispanic man who presented to the outpatient psychiatry department after being seen by a neurologist for a transient ischemic attack 6 months ago in the emergency department (ED). Upon outpatient presentation, he described episodes of dizziness, paranoia, and fear from feeling unsafe in his house due to rejecting that his home and family were his, insisting that they were identical imposters, all of which were concerns that his wife confirmed. He endorsed persistent visual hallucinations involving shadows taking human form and faces involving auditory hallucinations from his time in the military, which he associated with witnessed war trauma. He presented significant dysphoria and anxiety over his fluctuating condition and memory problems (Montreal Cognitive Assessment12,13 score: 16/30). Mr A displayed concern that he would be sent back to his home country to be killed despite secure immigration status.

Evaluation of the patient’s magnetic resonance image (Figure 1), which was obtained during his visit to the ED, showed multiple foci of white matter hyperintensities (increased T2 and fluid-attenuated inversion recovery white matter signal change) scattered throughout the right frontal lobe, bilateral occipital-temporal junctions, bilateral occipital horns of the lateral ventricles, and anterior margin of the body of the corpus callosum. He denied history of illicit drug use. He also reported being nonadherent to rivastigmine, citing edema and pruritus as side effects. Upon assessment, we provided psychoeducation, bilingual support for the family, and dementia resources. We initiated quetiapine, a second-generation antipsychotic with ample evidence of use in psychosis related to DLB.14–16 To further optimize his care, we used a collaborative model, consisting of a referral by a psychiatric nurse manager to a specialized cognitive neurology clinic, which coordinates with psychiatric services in the same institution. Although our psychiatric services are separate from family medicine, the psychiatrist coordinates the treatment plan with the patient’s family medicine provider through the electronic health record.

Discussion

Young-onset DLB with CS presents unique challenges. Patients presenting with DLB who begin expressing signs of a misidentification disorder should be evaluated as early as possible to rule out any underlying etiology that can be effectively treated. Although posttraumatic stress disorder was considered in the differential diagnosis, Mr A denied previous history of intrusive thoughts about his trauma, reexperiencing of events, or hypervigilance prior to being seen in the ED for a possible transient ischemic attack. Usually, transient ischemic attacks are associated with non-neurodegenerative disorders and CS, occurring at a younger age3; however, Mr A’s clinical examination and documented white matter changes are consistent with dementia.

To improve care in patients with young-onset DLB dementia and CS, crisis intervention resources should be provided to the patient and caregiver since CS is associated with an increased risk for self-harm, violent behaviors, and high mortality.8,17 Collaborative care models between primary care providers, neurologists, and psychiatrists should be highly considered. Early detection of CS may also help reduce caregiver stress, thus improving both patient and caregiver outcomes.18

Published online: June 21, 2022.
Relevant financial relationships: None.
Funding/support: None.
Patient consent: Consent was obtained from the patient to publish the case report, and information was de-identified to protect patient anonymity.

  1. Pennsylvania State University College of Medicine, Hershey, Pennsylvania
  2. Department of Psychiatry and Behavioral Health, Pennsylvania State University College of Medicine, Hershey, Pennsylvania
  3. Corresponding author: Ailyn Diaz, MD, Department of Psychiatry and Behavioral Health, 500 University Dr, Hershey, PA 17033 ([email protected]).
  1. Galvin JE. Lewy body dementia. Practical Neurol. 2019:67–71. Accessed August 11, 2021. https://practicalneurology.com/articles/2019-june/lewy-body-dementia-1/pdf PubMed
  2. Thaipisuttikul P, Lobach I, Zweig Y, et al. Capgras syndrome in dementia with Lewy bodies. Int Psychogeriatr. 2013;25(5):843–849. PubMed CrossRef
  3. Josephs KA. Capgras syndrome and its relationship to neurodegenerative disease. Arch Neurol. 2007;64(12):1762–1766. PubMed CrossRef
  4. Harciarek M, Kertesz A. The prevalence of misidentification syndromes in neurodegenerative diseases. Alzheimer Dis Assoc Disord. 2008;22(2):163–169. PubMed CrossRef
  5. Kuruppu DK, Matthews BR. Young-onset dementia. Semin Neurol. 2013;33(4):365–385. PubMed CrossRef
  6. Aiba Y, Sakakibara R, Ogata T, et al. Young-onset dementia with Lewy bodies. Case Rep Neurol. 2018;10(3):363–368. PubMed CrossRef
  7. Sanford AM. Lewy body dementia. Clin Geriatr Med. 2018;34(4):603–615. PubMed CrossRef
  8. Jain SB, Shah K, Wadhwa R. Capgras syndrome. NCBI website. Accessed August 2, 2021. https://www.ncbi.nlm.nih.gov/books/NBK570557/
  9. Leis K, Mazur E, Racinowski M, et al. Delusional misidentification syndrome: dissociation between recognition and identification processes. Acta Neuropsychol. 2019;17(4):456–467. CrossRef
  10. Koc AE, Hocaoglu C. What Is Capgras syndrome? Diagnosis and treatment approach. IntechOpen website. Accessed August 11, 2021. https://www.intechopen.com/chapters/71110
  11. Stinton C, McKeith I, Taylor J-P, et al. Pharmacological management of Lewy body dementia: a systematic review and meta-analysis. Am J Psychiatry. 2015;172(8):731–742. PubMed CrossRef
  12. Damian AM, Jacobson SA, Hentz JG, et al. The Montreal Cognitive Assessment and the Mini-Mental State Examination as screening instruments for cognitive impairment: item analyses and threshold scores. Dement Geriatr Cogn Disord. 2011;31(2):126–131. PubMed CrossRef
  13. Nasreddine ZS, Phillips NA, Bédirian V, et al. The Montreal Cognitive Assessment, MoCA: a brief screening tool for mild cognitive impairment. J Am Geriatr Soc. 2005;53(4):695–699. PubMed CrossRef
  14. Takahashi H, Yoshida K, Sugita T, et al. Quetiapine treatment of psychotic symptoms and aggressive behavior in patients with dementia with Lewy bodies: a case series. Prog Neuropsychopharmacol Biol Psychiatry. 2003;27(3):549–553. PubMed CrossRef
  15. Prohorov T, Klein C, Miniovitz A, et al. The effect of quetiapine in psychotic parkinsonian patients with and without dementia. an open-labeled study utilizing a structured interview. J Neurol. 2006;253(2):171–175. PubMed CrossRef
  16. Kurlan R, Cummings J, Raman R, et al; Alzheimer’s Disease Cooperative Study Group. Quetiapine for agitation or psychosis in patients with dementia and parkinsonism. Neurology. 2007;68(17):1356–1363. PubMed CrossRef
  17. Koedam ELGE, Pijnenburg YAL, Deeg DJH, et al. Early-onset dementia is associated with higher mortality. Dement Geriatr Cogn Disord. 2008;26(2):147–152. PubMed CrossRef
  18. Zweig YR, Galvin JE. Lewy body dementia: the impact on patients and caregivers. Alzheimers Res Ther. 2014;6(2):21. PubMed CrossRef